Iradimed Corporation (NASDAQ:IRMD) Shares Sold by Jane Street Group LLC

Jane Street Group LLC cut its holdings in Iradimed Corporation (NASDAQ:IRMD) by 43.4% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 6,243 shares of the medical equipment provider’s stock after selling 4,782 shares during the quarter. Jane Street Group LLC’s holdings in Iradimed were worth $314,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IRMD. Charles Schwab Investment Management Inc. raised its position in shares of Iradimed by 189.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 66,632 shares of the medical equipment provider’s stock valued at $3,351,000 after buying an additional 43,635 shares during the last quarter. Eagle Asset Management Inc. purchased a new position in shares of Iradimed during the 3rd quarter worth $1,239,000. Allspring Global Investments Holdings LLC boosted its holdings in shares of Iradimed by 14.4% during the third quarter. Allspring Global Investments Holdings LLC now owns 20,122 shares of the medical equipment provider’s stock worth $1,012,000 after purchasing an additional 2,538 shares during the last quarter. Albert D Mason Inc. purchased a new stake in shares of Iradimed in the third quarter valued at $737,000. Finally, Algert Global LLC increased its stake in Iradimed by 84.1% in the second quarter. Algert Global LLC now owns 26,774 shares of the medical equipment provider’s stock valued at $1,176,000 after purchasing an additional 12,227 shares during the last quarter. Institutional investors and hedge funds own 92.34% of the company’s stock.

Iradimed Price Performance

Shares of IRMD stock opened at $58.21 on Friday. Iradimed Corporation has a 1-year low of $40.18 and a 1-year high of $58.41. The firm’s 50-day simple moving average is $54.02 and its 200-day simple moving average is $49.46. The firm has a market cap of $737.70 million, a P/E ratio of 39.87 and a beta of 0.81.

Iradimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were given a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 1.03%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s payout ratio is 41.10%.

Insider Activity

In related news, CFO John Glenn sold 2,500 shares of Iradimed stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total transaction of $135,450.00. Following the sale, the chief financial officer now owns 4,383 shares of the company’s stock, valued at $237,470.94. The trade was a 36.32 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 37.10% of the company’s stock.

Iradimed Company Profile

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device.